Intracranial Efficacy of Next-Generation ALK-Targeted Therapies

November 8, 2024

Balazs Halmos, MD, Julia Rotow, MD, Christine Bestvina, MD, Shirish Gadgeel, MD

Peer Exchange | <b>Latest Advances in ALK-Positive and BRAF-Positive V600E NSCLC: Efficacy Updates, Brain Metastases Management, and Optimal Treatment Sequencing </b>

Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.

All: Please discuss the efficacy of ALK inhibitors in brain metastases.
1. REMARK study (Xiong A, et al. 2024. WCLC. OA09.03)
2. CROWN trial (Solomon BJ, et al. Lancet Respir Med. 2023)
3. ALTA-3 (Yang JC, et al. J Thorac Oncol. 2023)
4. ALTA-1L/brigatinib (Camidge DR, et al. J Clin Oncol. 2021)
Others